Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01374360 · ClinicalTrials.gov registry record
Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry
A clinical trial, sponsored by Alexion Pharmaceuticals.
- Completed
- Registry status
- 6,061
- Enrollment target
NCT01374360: Completed study, sponsored by Alexion Pharmaceuticals.
NCT01374360 is a clinical trial that has completed, run by Alexion Pharmaceuticals. The registered enrollment target is 6,061 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01374360 has completed, sponsored by Alexion Pharmaceuticals.
- COMPLETED
- Registry status
- 6,061 participants
- Enrollment target
Study Summary
This study is a collection of data to evaluate safety and characterize progression of Paroxysmal Nocturnal Hemoglobinuria (PNH).
Primary Outcome
Primary analyses will assess safety endpoints, including occurrence and time to first event for the following: meningococcal infections, infections with serious outcomes, formation of human anti-drug antibodies (ADA) to Soliris and Ultomiris, malignancy, thrombotic events, pulmonary hypertension, impaired renal function, impaired hepatic function, hemolysis, pregnancies, lactation, infusion reactions, bone marrow transplant, serious adverse events, and mortality.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6,061 participants |
| Start Date | 2004-10-29 |
| Est. Completion | 2025-04-14 |
What the finished NCT01374360 record still lists
NCT01374360 is an observational study that tracks outcomes without assigning an intervention. Its 6,061 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT01374360 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01374360 about?
NCT01374360 is a clinical study titled "Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry". This study is a collection of data to evaluate safety and characterize progression of Paroxysmal Nocturnal Hemoglobinuria (PNH).
What is the current status of trial NCT01374360?
This trial is currently completed. The enrollment target is 6,061 participants. The study started on 2004-10-29. Estimated completion is 2025-04-14.
Who is sponsoring clinical trial NCT01374360?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07166861 · 6,080 participants · NA
Annual Wellness Visits vs GRACE-augmented Annual Wellness Visits For Older Adults With High Needs - Phase 2
- NCT05884190 · 6,030 participants · NA
Trauma-informed Approach to Timely Detection and Management of Early Postpartum Hypertension
- NCT00005095 · 6,000 participants
Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
- NCT00280202 · 6,000 participants
Detection of Genetic Markers of Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI